

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that the special resolutions as set out in the EGM Notice dated 26 July 2021 were duly passed at the EGM held on 9 September 2021.

RESULTS OF THE EGM

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) and the circular (the “**Circular**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”), both dated 26 July 2021. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context herein requires otherwise.

The board of directors (the “**Board**”) is pleased to announce that the special resolutions as set out in the EGM Notice were duly passed by way of poll at the extraordinary general meeting (the “**EGM**”) held on 9 September 2021.

As at the date of the EGM, the Company had 1,894,500,000 Shares in issue including 697,500,000 Domestic Shares and 1,197,000,000 H Shares. Prior to the date of the EGM, Shareholders holding 1,726,574,500 Shares, representing approximately 91.14% of the total number of the Shares in issue as at the date of the EGM, had notified to the Company that they will attend the EGM either in person or by proxy. The actual number of the Shares attending the EGM either in person or by proxy was 662,500,000, representing approximately 34.97% of the total number of the Shares in issue as at the date of the EGM. The holding of the EGM shall comply with the Company Law of the PRC and the Articles of Association.

No Shareholder was required to abstain from voting in respect of the resolutions at the EGM. As such, there were a total of 1,894,500,000 Shares entitling the Shareholders to attend and vote on the resolutions at the EGM.

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 17.47A of the GEM Listing Rules. No Shareholder has stated in his/her intention to vote against or to abstain from voting on any resolutions at the EGM.

Details of the poll results in respect of the resolutions proposed at the EGM were as follows:

Special Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
(a)	To approve, ratify and confirm the amended and restated settlement agreement (the “ Amended and Restated Settlement Agreement ”) dated 26 March 2021 entered into among the Company, HONGKONG TEDA Biomedical Investment Limited (“ Hong Kong TEDA ”), Shu Ju Ku Inc. (“ SJK ”) and Shu Ju Ku Greater China Ltd. (“ SJKGC ”) which shall amend, replace and supersede the agreement dated 16 April 2016 entered into among the Company, SJK and SJKGC in relation to the acquisition of 51% equity interest in SJKGC at a total consideration of US\$27,000,000 and the transactions contemplated thereunder	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares
(b)	To approve, ratify and confirm the supplemental share purchase agreement (the “ Supplemental Share Purchase Agreement ”) in respect of the share purchase agreement dated 16 April 2016 (as amended and supplemented by two supplemental agreements dated 25 April 2016 and 12 September 2019) dated 26 March 2021 entered into among the Company, SJK and SJKGC and the transactions contemplated thereunder	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares
(c)	To approve, ratify and confirm the amended and restated shareholders’ agreement (the “ Amended and Restated Shareholders’ Agreement ”) dated 26 March 2021 entered into among the Company, Hong Kong TEDA, SJK and SJKGC and the transactions contemplated thereunder	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares

Special Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
(d)	To approve, ratify and confirm the supplemental lease agreement (the “ Supplemental Lease Agreement ”) dated 1 May 2020 entered into between Guangdong Fulilong Fertilizers Factory Co., Ltd.* (廣東福利龍複合肥有限公司) and Guangdong Lvzhou Ecology Engineering Co., Ltd.* (廣東綠洲生態工程有限公司) and the transactions contemplated thereunder	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares
(e)	To generally and unconditionally approve, ratify and confirm all actions taken or to be taken by the Company pursuant to the Amended and Restated Settlement Agreement, the Supplemental Share Purchase Agreement, the Amended and Restated Shareholders’ Agreement and the Supplemental Lease Agreement	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares
(f)	THAT any one or more of the directors of the Company (the “ Directors ”) be and is/are hereby authorised to implement and take all steps and do all acts and things and execute all such documents (including under seal, where applicable) which he/she/they consider(s) necessary, desirable or expedient to give effect to the Agreements and the transactions contemplated thereunder and to agree with such variation, amendment or waiver as, in the opinions of the Directors, in the interests of the Company and its shareholders as a whole	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares

Note: The percentages of votes are calculated based on the total number of the Shares held by the Shareholders who voted at the EGM either in person or by corporate representative or proxy.

As more than two-thirds of the votes present at the EGM either in person or by proxy had voted in favour of the above special resolution numbered (a) to (f), the above resolutions were duly passed as special resolutions.

Peking Certified Public Accountants, the Company's external accountants who are qualified to serve as its auditors was appointed as the scrutineer of the EGM for the vote-taking.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
9 September 2021

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive Directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the Directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

This announcement will remain on the "Latest Listed Company Information" page on the GEM website at www.hkgem.com for at least seven days from the date of its posting. This announcement will also be published and remain on the website of the Company at www.bioteda.com.